NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

NRx Pharmaceuticals received FDA approval for an Expanded Access Protocol allowing the use of NRX-101 to augment Transcranial Magnetic Stimulation (TMS) in treating depression. The protocol provides regulated access to NRX-101 for patients who cannot participate in the ongoing pivotal SPARC-TMS trial, addressing safety concerns related to compounded D-cycloserine.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.